Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
Mycobacterium bovis bacillus Calmette–Guerin (BCG) remains at the forefront of immunotherapy for treating bladder cancer patients. However, the incidence of recurrence and progression to invasive cancer is commonly observed. There are no established effective intravesical therapies available for pat...
Main Authors: | Julieti Huch Buss, Karine Rech Begnini, Camila Bonemann Bender, Adriana R. Pohlmann, Silvia S. Guterres, Tiago Collares, Fabiana Kömmling Seixas |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00977/full |
Similar Items
-
Auxotrophic <i>Mycobacterium bovis</i> BCG: Updates and Perspectives
by: Odir Antônio Dellagostin, et al.
Published: (2022-05-01) -
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01) -
BCG in Bladder Cancer Immunotherapy
by: Song Jiang, et al.
Published: (2022-06-01) -
Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group
by: Kyle M. Rose, et al.
Published: (2022-09-01) -
Linfadenitis supurada por BCG: Reporte de un caso Supurative lymphadenitis caused by BCG: A case report
by: Isabel Martínez Grau, et al.
Published: (2005-08-01)